Mirna-and lncrna-based therapeutics for non-hodgkin’s lymphoma: Moving towards an rna-guided precision medicine

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Increasing evidence has demonstrated the functional roles of miRNAs and lncRNAs in lymphoma onset and progression, either by acting as tumor-promoting ncRNAs or as tumor sup-pressors, emphasizing their appeal as lymphoma therapeutics. In fact, their intrinsic ability to mod-ulate multiple dysregulated genes and/or signaling pathways makes them an attractive therapeutic approach for a multifactorial pathology like lymphoma. Currently, the clinical application of miRNA-and lncRNA-based therapies still faces obstacles regarding effective delivery systems, off-target effects, and safety, which can be minimized with the appropriate chemical modifications and the development of tumor site-specific delivery approaches. Moreover, miRNA-and lncRNA-based therapeutics are being studied not only as monotherapies but also as complements of standard treatment regimens to provide a synergic effect, improving the overall treatment efficacy and reducing the therapeutic resistance. In this review, we summarize the fundamentals of miRNA-and lncRNA-based therapeutics by discussing the different types of delivery systems, with a focus on those that have been investigated in lymphoma in vitro and in vivo. Moreover, we described the ongoing clinical trials of novel miRNA-and lncRNA-based therapeutics in lymphoma.

Cite

CITATION STYLE

APA

Fernandes, M., Marques, H., Teixeira, A. L., & Medeiros, R. (2021, December 1). Mirna-and lncrna-based therapeutics for non-hodgkin’s lymphoma: Moving towards an rna-guided precision medicine. Cancers. MDPI. https://doi.org/10.3390/cancers13246324

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free